Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
India
· Delayed Price · Currency is INR | Market Cap | 37.80B |
| Revenue (ttm) | 7.10B |
| Net Income (ttm) | 1.52B |
| Shares Out | 111.93M |
| EPS (ttm) | 13.59 |
| PE Ratio | 24.85 |
| Forward PE | 22.48 |
| Dividend | 5.20 (1.52%) |
| Ex-Dividend Date | n/a |
| Volume | 248,042 |
| Average Volume | 276,849 |
| Open | 342.00 |
| Previous Close | 342.00 |
| Day's Range | 333.70 - 344.05 |
| 52-Week Range | 251.95 - 366.25 |
| Beta | 0.45 |
| RSI | 72.76 |
| Earnings Date | May 15, 2026 |
About NSE:ADVENZYMES
Advanced Enzyme Technologies Limited, together with its subsidiaries, engages in the research, development, manufacture, and marketing of enzymes and probiotics in India, Europe, the United States, Asia, and internationally. The company offers enzymes and probiotics-based nutritional supplements for human healthcare and nutrition, animal nutrition, fruit and vegetable processing, baking, brewing and malting, starch and grain processing, protein modification, yeast processing, dairy and cheese processing, and oils and fats processing, as well as... [Read more]
Financial Performance
In fiscal year 2025, NSE:ADVENZYMES's revenue was 6.37 billion, an increase of 2.09% compared to the previous year's 6.24 billion. Earnings were 1.31 billion, a decrease of -1.64%.
Financial StatementsNews
Advanced Enzyme Technologies announces resignation of senior vice president
Advanced Enzyme Technologies has announced the resignation of Mr. Dipak Roda, Senior Vice President - Marketing and Business Development. His resignation will be effective from the close of business h...
Advanced Enzyme Technologies Ltd (BOM:540025) Q3 2026 Earnings Call Highlights: Resilient ...
Advanced Enzyme Technologies Ltd (BOM:540025) Q3 2026 Earnings Call Highlights: Resilient Revenue Growth Amid Market Challenges
Q3 2026 Advanced Enzyme Technologies Ltd Earnings Call Transcript
Q3 2026 Advanced Enzyme Technologies Ltd Earnings Call Transcript
Advanced Enzyme Technologies Transcript: Q3 25/26
Q3 FY26 saw 2% YoY revenue growth but a 7% sequential decline, with EBITDA margin at 29%. Human Healthcare declined, while Animal Healthcare and Bioprocessing grew. Management targets 13–15% annual growth, with new R&D and B2C initiatives supporting future expansion.
Advanced Enzyme Technologies Ltd (BOM:540025) Q2 2026 Earnings Call Highlights: Strong ...
Advanced Enzyme Technologies Ltd (BOM:540025) Q2 2026 Earnings Call Highlights: Strong Year-on-Year Growth Amidst Tariff Challenges
Q2 2026 Advanced Enzyme Technologies Ltd Earnings Call Transcript
Q2 2026 Advanced Enzyme Technologies Ltd Earnings Call Transcript
Advanced Enzyme Technologies Transcript: Q2 25/26
Q2 FY26 saw 26% YoY revenue growth and 42% YoY EBITDA growth, with broad-based gains across all segments. Management maintains mid-teens growth guidance due to tariff and global uncertainties, while R&D investment and new product development remain key priorities.
Advanced Enzyme shares jump 9% today after Q2 profit rises 32% YoY to Rs 43.3 crore
Shares of Advanced Enzyme Technologies Ltd. surged as much as 9% on Wednesday, November 12, after the company announced its...
Advanced Enzyme Technologies Transcript: Q1 25/26
Record quarterly revenue and double-digit growth were driven by strong human and animal healthcare segments, with margins impacted by tariffs and product mix. Management remains optimistic for sustained double-digit growth, supported by ongoing R&D investment and new business initiatives.
Advanced Enzyme Technologies Transcript: Q4 24/25
Revenue grew 2% year-over-year to INR 6,369 million in FY25, with EBITDA margin at 31% and PAT margin at 21%. Management expects mid double-digit growth in FY26, led by biocatalyst and human nutrition, while maintaining current margin levels.
Advanced Enzyme Technologies Transcript: Q3 24/25
Q3 FY25 saw 5% year-over-year and 16% sequential revenue growth, with strong margins and segmental gains in bioprocessing and specialized manufacturing. Management expects single-digit growth for FY25, with a focus on innovation, U.S. expansion, and strategic acquisitions amid global uncertainties.
Advanced Enzyme Technologies Transcript: Q2 24/25
Q2 saw revenue growth but margin pressure due to deferred sales and higher costs. Full-year growth guidance was revised to single digits, with H2 expected to be stronger as deferred revenue is recognized. U.S. sales remain robust, while R&D investment and new product development continue.
Advanced Enzymes shares fall 8% after weak Q2 FY25 results
Advanced Enzyme Technologies shares dropped over 8% in morning trading following disappointing Q2 FY25 results. The company reported a 7.4% year-over-year revenue drop to ₹146.1 crore, down from ₹157....
Advanced Enzyme Technologies Q2 FY25: Revenue declines 7.4% YoY to ₹146.1 crore, Net Profit falls 5.1% YoY
Advanced Enzyme Technologies recently released its financial results for the second quarter of FY25, showing a decrease in both revenue and net profit compared to the same period last year. The compan...
Advanced Enzyme Technologies Transcript: Q1 24/25
Q1 FY25 delivered 5% revenue and 19% PAT growth year-over-year, with strong US sales offsetting softness in India and Europe. Management expects 12%-14% full-year growth, stable margins, and most gains in H2, supported by new product launches and ongoing R&D investment.